

Lixisenatide

Cat. No.: HY-P0119
CAS No.: 320367-13-3
Molecular Formula: C₂₁₅H₃₄₇N₆₁O₆₅S
Molecular Weight: 4858.49
Sequence Shortening: HGEGETFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKSKKKKK-NH₂
Target: GCGR
Pathway: GPCR/G Protein
Storage: Sealed storage, away from moisture
 Powder -80°C 2 years
 -20°C 1 year

HGEGETFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKSKKKKK-NH₂

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro

H₂O : 100 mg/mL (20.58 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent	1 mg	5 mg	10 mg
	Concentration	Mass		
1 mM		0.2058 mL	1.0291 mL	2.0583 mL
5 mM		0.0412 mL	0.2058 mL	0.4117 mL
10 mM		0.0206 mL	0.1029 mL	0.2058 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).

IC₅₀ & Target GLP-1 receptor^{[1][2]}.

CUSTOMER VALIDATION

- J Mol Neurosci. 2020 Feb 10.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Ahrén B et al. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. *Diabetes Ther.* 2016 Jun 18
- [2]. Lorenz M, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia. *Regul Pept.* 2013 Aug 10;185:1-8.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA